Cipla Ltd

CIPLA

Watchlist

AI Mode

‌

Market Cap

₹ 1,20,919 Cr

P/E

22.22

‌

Investment Checklist

How to read checklist?

Performance

STEADY PERFORMER

Valuation

REASONABLE

Growth

STABLE

Profitability

HIGH MARGIN

Technicals

Bearish

Risk

LOW RISK

Investment Checklist

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

‌
‌

‌

Price

PE Ratio

Price

‌

Overview

Detailed Summary

Cipla Limited is a leading Indian pharmaceutical company engaged in the manufacture, development, and marketing of a broad range of branded and generic formulations and APIs.

The company achieved its highest-ever quarterly revenue in Q2 FY26, reaching INR 7,589 Cr with robust EBITDA margins of 25%, highlighting excellent financial performance.

Cipla's strategic partnership with Eli Lilly to launch Yurpeak in India marks a significant expansion in chronic care, specifically targeting diabetes, which affects millions in India.

Cipla has made significant strides in respiratory care in North America, ranking as the top albuterol MDI supplier with a market share of 22%, reaffirming its leadership in the respiratory space.

Strategic investments and partnerships in biotechnology and generics underline Cipla's focus on expanding its presence in advanced therapeutic segments and maintaining competitive advantage.

Sector

Pharmaceuticals

Industry

Pharmaceuticals - Indian - Bulk Drugs & Formln Lrg

Market Cap

1,20,919 Cr

Volatility

Moderate Risk

P/E Ratio

22.2

Industry P/E

27.7

PEG Ratio

7.6

P/B Ratio

3.7

52W High

1,672.20

52W Low

1,310.05

Sales CAGR

6.88%

7.38%

8.51%

10Y

5.15%

Profit CAGR

27.33%

21.40%

17.34%

10Y

15.03%

ROE

TTM

16.53%

14.91%

14.09%

10Y

12.46%

ROCE

TTM

21.05%

20.09%

18.88%

10Y

15.55%

Technicals

Oscillators

BearishNeutralBullish

Neutral

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Moving Averages

BearishNeutralBullish

Bearish

Neutral

Bullish

Overall

BearishNeutralBullish

Bearish

Neutral

Bullish

Forecasts

No. of Analysts

44

1Y Price Target

1715.26 ▲ 14.42%

Q3 EPS Estimate

Q3 Revenue Estimate

Unlock Premium Features

Price, EPS and Revenue Projections

Strong SellSellHoldBuyStrong Buy

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

updated on

Dec 03, 2025

Peers

Symbol	Price	Market Cap	P/E	P/B	Div Yield (%)	ROE (%)	ROCE (%)	ROA (%)
CIPLA	1497.45	1,20,919 Cr	22.22	3.67	1.07	16.53	21.05	13.58
DRREDDY	1271.00	1,06,165 Cr	18.39	2.95	0.63	16.03	18.66	10.55
LUPIN	2109.70	96,528 Cr	22.32	4.92	0.57	22.03	21.92	12.98
ZYDUSLIFE	917.85	92,408 Cr	18.36	3.65	1.20	19.44	19.08	10.60
MANKIND	2110.20	87,110 Cr	49.82	5.70	0.00	11.45	12.34	6.16
AUROPHARMA	1189.10	69,293 Cr	20.25	1.98	0.00	9.77	12.69	6.51
ALKEM	5614.05	67,284 Cr	28.63	5.04	0.80	17.69	18.13	11.89

Financial Statements

AI Powered Summary

Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

View Standalone

Total Figures

QoQ Changes

Total Figures

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Sales	6,329	6,678	6,604	6,163	6,694	7,051	7,073	6,730	6,957	7,589
Expenses	4,835	4,944	4,856	4,847	4,978	5,165	5,084	5,192	5,179	5,695
Operating Profit	1,494	1,734	1,748	1,316	1,716	1,886	1,989	1,538	1,778	1,895
OPM %	23.60	25.96	26.46	21.35	25.63	26.74	28.12	22.85	25.56	24.97
Other Income	136	176	-10	249	160	191	222	289	259	269
Interest	16	26	30	18	18	15	15	14	14	13
Depreciation	239	290	233	288	247	272	280	309	253	297
Profit Before Tax	1,375	1,594	1,474	1,259	1,611	1,789	1,916	1,504	1,770	1,854
Tax %	27.50	27.50	27.50	25.80	27.00	27.00	17.35	18.57	27.00	27.00
Net Profit	997	1,156	1,069	934	1,176	1,306	1,584	1,225	1,292	1,353
EPS in Rs	12.32	13.99	13.06	11.61	14.58	16.12	19.43	15.12	16.06	16.72

Consolidated Profit Loss (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	TTM
Sales	14,630	15,219	16,362	17,132	19,160	21,763	22,753	25,774	27,548	27,811
Expenses	11,919	12,329	13,265	13,926	14,907	17,211	17,726	19,483	20,420	20,621
Operating Profit	2,712	2,890	3,097	3,206	4,252	4,553	5,027	6,291	7,128	7,190
OPM %	18.54	18.99	18.93	18.71	22.19	20.92	22.09	24.41	25.87	25.85
Other Income	229	280	477	344	266	99	293	552	862	960
Interest	159	114	168	197	161	106	110	90	62	58
Depreciation	1,323	1,323	1,326	1,175	1,068	1,052	1,172	1,051	1,107	1,113
Profit Before Tax	1,222	1,669	2,079	2,178	3,290	3,493	4,038	5,702	6,821	6,979
Tax %	14.71	14.98	27.39	28.98	27.01	26.73	29.79	27.12	22.43	22.53
Net Profit	1,042	1,419	1,510	1,547	2,401	2,559	2,835	4,155	5,291	5,407
EPS in Rs	12.43	17.44	18.88	19.13	29.73	31.11	34.67	50.99	65.24	67.32
Dividend Payout %	16.00	17.14	15.85	20.88	16.78	16.04	24.50	25.49	24.52	—

Consolidated Balance Sheet (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Equity Capital	161	161	161	161	161	161	161	161	161	162
Reserves	11,356	12,383	14,068	14,851	15,602	18,165	20,680	23,246	26,545	31,032
Borrowings	5,192	4,113	4,098	4,316	2,816	2,014	1,056	803	559	438
Other Liabilities	4,420	4,381	4,533	4,635	5,083	4,811	5,204	5,252	5,452	5,755
Total Liabilities	21,128	21,037	22,861	23,963	23,663	25,152	27,101	29,463	32,718	37,387
Fixed Assets	9,368	9,490	9,949	9,547	9,559	9,394	9,622	9,101	9,494	9,895
CWIP	2,061	1,683	981	676	825	969	766	1,093	1,153	1,566
Investments	759	975	1,260	2,616	1,595	2,832	2,612	3,722	5,563	8,044
Other Assets	8,940	8,889	10,670	11,125	11,684	11,957	14,101	15,547	16,509	17,882
Total Assets	21,128	21,037	22,861	23,963	23,663	25,152	27,101	29,463	32,718	37,387

Consolidated Cash Flows (in ₹ Crores)

View Standalone

Total Figures

YoY Changes

Total Figures

	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
Cash from Operating Activity	1,741	2,382	1,463	1,691	3,068	3,755	3,326	3,238	4,134	5,005
Cash from Investing Activity	-4,523	-1,310	-854	-1,669	104	-2,387	-1,872	-2,389	-2,988	-3,691
Cash from Financing Activity	3,104	-1,326	-385	-349	-2,949	-1,240	-1,600	-958	-1,200	-1,293
Net Cash Flow	322	-254	223	-326	224	129	-146	-109	-55	21

Shareholdings

Shareholding History

Quarterly

Yearly

Quarterly

	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025
Promoters	33.61%	33.55%	33.47%	33.47%	33.47%	33.47%	30.91%	30.92%	29.19%	29.20%	29.19%	29.21%
FIIs	28.39%	27.41%	25.49%	25.74%	25.73%	25.83%	27.81%	28.80%	26.65%	26.28%	25.24%	24.54%
DIIs	21.13%	22.10%	24.34%	24.19%	24.34%	24.42%	24.95%	24.17%	27.72%	28.16%	29.26%	30.25%
Public	16.87%	16.94%	16.70%	16.60%	16.46%	16.28%	16.33%	16.11%	16.44%	16.37%	16.30%	15.99%
Total Shareholders	4,04,182	4,75,293	4,66,513	4,26,861	4,25,731	4,36,154	4,63,569	4,70,234	5,25,114	5,43,420	5,49,655	5,34,587

Market Transactions

Date	Party	Category	Type	Avg Price (₹)	Total Value (₹)	Quantity	Percent Traded
Dec 02, 2024	Samina hamied	Bulk	Sell	1,518.75	1,360.00 Cr	89,54,750	1.10
Dec 02, 2024	Rumana hamied	Bulk	Sell	1,518.75	750.76 Cr	49,43,250	0.61
Aug 22, 2024	Anusha jain	Insider - Immediate Relative	Disposal	1,590.83	0.32 Cr	2,000	—
Aug 14, 2024	Anusha jain	Insider - Immediate Relative	Disposal	1,587.95	0.48 Cr	3,000	—
May 15, 2024	Samina hamied	Bulk	Sell	1,345.00	1,204.41 Cr	89,54,750	1.10
May 15, 2024	Shirin hamied	Bulk	Sell	1,345.00	855.82 Cr	63,63,000	0.78
May 15, 2024	Rumana hamied	Bulk	Sell	1,345.00	664.87 Cr	49,43,250	0.61
May 15, 2024	Icici prudential mutual fund	Bulk	Buy	1,345.00	743.25 Cr	55,25,999	0.68
Oct 18, 2023	Jaideep mallick	Insider - Immediate Relative	Acquisition	1,269.80	0.02 Cr	150	—
Oct 18, 2023	Priyanka mallick	Insider - Designated Person	Acquisition	1,273.28	0.06 Cr	500	—

Projection

Unlock Premium Features

Get In-depth insights on EPS and Revenue forecasts

Actions

Action Type

‌
‌

Announcements

Last 7 days

Newest

Sentiment

Corporate Action

1 day ago

Allotment of Equity Shares Under ESOP Scheme

The company has allotted 585 fully paid-up equity shares under the Employee Stock Option and Stock Appreciation Rights Schemes, increasing its paid-up capital.

Documents

Presentations

Concalls

Reports

Presentations

Investor Presentation

Q2 FY26

Investor Presentation

Q1 FY26

Investor Presentation

Q4 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q3 FY25

Investor Presentation

Q2 FY25

Investor Presentation

Q1 FY25

Investor Presentation

Q4 FY24

Showing 1 - 8 of 40

AI Mode

Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.

AI Mode

Cipla

Cipla Ltd

CIPLA

AI Mode

Investment Checklist

Investment Checklist

Overview

Sector

Industry

Market Cap

Volatility

P/E Ratio

Industry P/E

PEG Ratio

P/B Ratio

52W High

52W Low

Technicals

Oscillators

Neutral

Overall

Bearish

Moving Averages

Bearish

Overall

Bearish

Forecasts

44

1715.26 ▲ 14.42%

Upgrade

Upgrade

Upgrade

Upgrade

Unlock Premium Features

Upgrade

Buy

Peers

Price Chart Comparison

Financial Statements

AI Powered Summary

AI Mode

Consolidated Quarterly Results (in ₹ Crores)

Consolidated Profit Loss (in ₹ Crores)

Consolidated Balance Sheet (in ₹ Crores)

Consolidated Cash Flows (in ₹ Crores)

Shareholdings

Shareholding History

Market Transactions

Projection

Unlock Premium Features

Upgrade

Actions

Announcements

Documents

AI Mode

AI Mode

Investment Checklist

Peers

Price Chart Comparison